Evaluation of antimetastatic activity in vemurafenib resistant melanoma cell lines after DM-1 treatment (2014)
- Authors:
- Autor USP: ENGLER, SILVYA STUCHI MARIA - FCF
- Unidade: FCF
- Subjects: MELANOMA; RESISTÊNCIA MICROBIANA ÀS DROGAS
- Language: Inglês
- Imprenta:
- Source:
- Título: Brazilian Journal of Pharmaceutical Sciences
- ISSN: 1984-8250
- Volume/Número/Paginação/Ano: v. 50, suppl. 1, p. 4 res. FCF003, 2014
- Conference titles: Pharmaceutical Science and Technology Meeting of the Faculty of Pharmaceutical Sciences
-
ABNT
SOUZA, Nayane de et al. Evaluation of antimetastatic activity in vemurafenib resistant melanoma cell lines after DM-1 treatment. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 11 jan. 2026. , 2014 -
APA
Souza, N. de, Ikeda, G. T., Faião-Flores, F., Pennacchi, P. C., Suárez, J. Q., & Maria-Engler, S. S. (2014). Evaluation of antimetastatic activity in vemurafenib resistant melanoma cell lines after DM-1 treatment. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. -
NLM
Souza N de, Ikeda GT, Faião-Flores F, Pennacchi PC, Suárez JQ, Maria-Engler SS. Evaluation of antimetastatic activity in vemurafenib resistant melanoma cell lines after DM-1 treatment. Brazilian Journal of Pharmaceutical Sciences. 2014 ; 50 4 res. FCF003.[citado 2026 jan. 11 ] -
Vancouver
Souza N de, Ikeda GT, Faião-Flores F, Pennacchi PC, Suárez JQ, Maria-Engler SS. Evaluation of antimetastatic activity in vemurafenib resistant melanoma cell lines after DM-1 treatment. Brazilian Journal of Pharmaceutical Sciences. 2014 ; 50 4 res. FCF003.[citado 2026 jan. 11 ] - Processo invasor do câncer cervical uterino: análise das metaloproteinases -2, -9, -14, TIMP-2 e do gene supressor de tumor RECK
- Organotypic models in drug development
- Evaluation of the expression of matrix metalloproteinase type 9 in cervicovaginal smears: a cytlogical study
- RECK is required for migration and invasiveness in melanoma after vemurafenib treatment
- Epithelial mesenchymal transition as an alternative pathway in vemurafenib and vemurafenib/trametinib chemoresistant melanoma
- Novel kojic acid derivatives ACT on melanogenesis and skin age-related enzymes
- Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma
- The combination of intermittent treatment of vemurafenib and DM-1 compound for melanoma therapies
- Apoptosis expression in vemurafenib-resistant melanoma cells induced by curcumin analog DM-1
- RECK-tumor suppressor gene is overexpressed in vermurafenib-resistant human melanoma cells
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
